| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Revenue | 0 | 70 | ||
| Research and development | 1,959 | 2,253 | ||
| General and administrative | 2,455 | 2,685 | ||
| Total operating expenses | 4,414 | 4,938 | ||
| Operating loss | -4,414 | -4,868 | ||
| Investment income, net | 183 | 216 | ||
| Other expense, net | -18 | -7 | ||
| Total other income | 165 | 209 | ||
| Net loss before benefit from income taxes and noncontrolling interests | -4,249 | -4,659 | ||
| Benefit from income taxes | 0 | 0 | ||
| Net loss | -4,249 | -4,659 | ||
| Less - net income (loss) attributable to noncontrolling interests | 0 | 0 | ||
| Net loss attributable to lisata therapeutics, inc. common stockholders | -4,249 | -4,659 | ||
| Basic shares (in shares) | 8,738,000 | 8,605,000 | ||
| Diluted shares (in shares) | 8,738,000 | 8,605,000 | ||
| Lisata therapeutics, inc. common stockholders - diluted (in usd per share) | -0.49 | -0.54 | ||
| Lisata therapeutics, inc. common stockholders- basic (in usd per share) | -0.49 | -0.54 | ||
LISATA THERAPEUTICS, INC. (LSTA)
LISATA THERAPEUTICS, INC. (LSTA)